title: Intraperitoneal administration of tumor-targeting Salmonella typhimurium A1-R inhibits disseminated human ovarian cancer and extends survival in nude mice.
abstract: Peritoneal disseminated cancer is highly treatment resistant. We here report the efficacy of intraperitoneal (i.p.) administration of tumor-targeting Salmonella typhimurium A1-R in a nude mouse model of disseminated human ovarian cancer. The mouse model was established by intraperitoneal injection of the human ovarian cancer cell line SKOV3-GFP. Seven days after implantation, mice were treated with S. typhimurium A1-R via intravenous (i.v.) or i.p. administration at the same dose, 5 × 10(7) CFU, once per week. Both i.v. and i.p. treatments effected prolonged survival compared with the untreated control group (P=0.025 and P<0.001, respectively). However, i.p. treatment was less toxic than i.v.
  
  
  METHODS
  Tumor-specific targeting of S. typhimurium A1-R was confirmed with bacterial culture from tumors and various organs and tumor or organ colony formation after i.v. or i.p. injection. Selective tumor targeting was most effective with i.p. administration. The results of the present study show S. typhimurium A1-R has promising clinical potential for disseminated ovarian cancer, especially via i.p. administration.
authors.affiliation: AntiCancer, Inc, San Diego, CA, USA.|Department of Surgery, University of California San Diego, San Diego, CA, USA.|Department of Frontier Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan.
authors.forename: Yasunori
authors.initials: Y
authors.lastname: Matsumoto
authors.affiliation: AntiCancer, Inc, San Diego, CA, USA.|Department of Surgery, University of California San Diego, San Diego, CA, USA.|Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Kanazawa University, Ishikawa, Japan.
authors.forename: Shinji
authors.initials: S
authors.lastname: Miwa
authors.affiliation: AntiCancer, Inc, San Diego, CA, USA.
authors.forename: Yong
authors.initials: Y
authors.lastname: Zhang
authors.affiliation: AntiCancer, Inc, San Diego, CA, USA.
authors.forename: Ming
authors.initials: M
authors.lastname: Zhao
authors.affiliation: AntiCancer, Inc, San Diego, CA, USA.|Department of Surgery, University of California San Diego, San Diego, CA, USA.
authors.forename: Shuya
authors.initials: S
authors.lastname: Yano
authors.affiliation: AntiCancer, Inc, San Diego, CA, USA.|Department of Surgery, University of California San Diego, San Diego, CA, USA.
authors.forename: Fuminari
authors.initials: F
authors.lastname: Uehara
authors.affiliation: AntiCancer, Inc, San Diego, CA, USA.|Department of Surgery, University of California San Diego, San Diego, CA, USA.
authors.forename: Mako
authors.initials: M
authors.lastname: Yamamoto
authors.affiliation: AntiCancer, Inc, San Diego, CA, USA.|Department of Surgery, University of California San Diego, San Diego, CA, USA.
authors.forename: Yukihiko
authors.initials: Y
authors.lastname: Hiroshima
authors.affiliation: AntiCancer, Inc, San Diego, CA, USA.|Department of Surgery, University of California San Diego, San Diego, CA, USA.
authors.forename: Makoto
authors.initials: M
authors.lastname: Toneri
authors.affiliation: Department of Surgery, University of California San Diego, San Diego, CA, USA.
authors.forename: Michael
authors.initials: M
authors.lastname: Bouvet
authors.affiliation: Department of Frontier Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan.
authors.forename: Hisahiro
authors.initials: H
authors.lastname: Matsubara
authors.affiliation: Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Kanazawa University, Ishikawa, Japan.
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Tsuchiya
authors.affiliation: AntiCancer, Inc, San Diego, CA, USA.|Department of Surgery, University of California San Diego, San Diego, CA, USA.
authors.forename: Robert M
authors.initials: RM
authors.lastname: Hoffman
mesh_terms: D000818:Animals; D058491:Bacterial Load; D001691:Biological Therapy / Q000379:methods*; D045744:Cell Line, Tumor; D005260:Female; D006801:Humans; D007274:Injections, Intraperitoneal; D007275:Injections, Intravenous; D008819:Mice, Nude; D010051:Ovarian Neoplasms / Q000382:microbiology / Q000473:pathology / Q000628:therapy*; D010534:Peritoneal Neoplasms / Q000382:microbiology / Q000473:pathology / Q000628:therapy*; D012486:Salmonella typhimurium / Q000254:growth & development / Q000472:pathogenicity*; D013997:Time Factors; D014774:Virulence; D023041:Xenograft Model Antitumor Assays
keywords: Salmonella typhimurium A1-R; bacterial therapy; mouse model; orthotopic; ovarian cancer